Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 18 Years to 40 Years; female; no BMI minimum stated; conditions: Polycystic Ovary Syndrome; Obesity; Infertility, Female
- Interventions
- GLP-1 receptor agonist; Metformin; healthy lifestyle education
- Conditions
- Polycystic Ovary Syndrome; Obesity; Infertility, Female
- Phase and size
- NA · 392 participants
- Dates
- Start 2025-03-01
Primary completion 2026-12-31 - Sponsor
- Peking University Third Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Live birth rate18 months
02Eligibility
Who can take part
Inclusion Criteria: Women with a wish to conceive; Women with PCOS (Rotterdam criteria); 28 kg/m2≤BMI\<35kg/m2; Exclusion Criteria: Women with medical morbidity; Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine anomalies or untreated tubal hydrosalpinx; Receiving a donor oocyte or donor sperm cycle; Chromosome abnormality or recurrent miscarriage; planning preimplantation genetic testing (PGT); Any other contraindications to fertility treatment; Allergic to or contraindicated for GLP-1 class medications.
03Change log
Registry changes
No changes recorded since the trial was added.